Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include thiolated nitro fatty acids. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

Abstract: A method of making an optical fiber-based sensor includes providing an optical fiber, and providing a sensing or protection layer on a surface of the optical fiber by an atomic layer deposition (ALD) process.

Abstract: A method of ink-extrusion printing an object, including providing a mixture including liquid crystal monomers and photo-catalyzing or heating the mixture to produce a liquid crystal ink. The ink is in a nematic phase. The method includes extruding the ink through a print-head orifice moving along a print direction to form an extruded film of the object. The extruded film exhibits birefringence. Also disclosed are a liquid crystal ink. The ink includes a mixture including liquid crystal monomers. The mixture when at a target printing temperature is in a nematic phase. Also disclosed is ink-extrusion-printed object. The object includes an extrusion-printed film including a nematic liquid crystal elastomer, wherein the film exhibits birefringence along an extrusion axis of the film.

Abstract: Methods of detecting platinum and copper in a test sample are provided. Kits for use in detecting platinum and copper in a test sample also are provided.

Abstract: Provided herein are coacervate compositions including cytokines, and methods of making and using the same. The coacervate can be formed by the mixing of an active agent, such as a drug or protein with the polyanion, such as heparin or heparan sulfate, and a custom-made polycation (e.g., PEAD or PELD). The coacervates can be used in the treatment of diseases and disorders where targeted treatment is desired, for example in treatment of cancers.

Abstract: A method of forming a microneedle array can include forming a microneedle array that has one or more bioactive component. The microneedle array can include a base portion and plurality of microneedles extending from the base portion, and the one or more bioactive components are present in a higher concentration in the plurality of microneedles than in the base portion.

Abstract: The invention relates to biodegradable, metal alloys, methods for their preparation and applications for their use. The alloys include magnesium and other components, such as, yttrium, calcium, zirconium, and zinc. These elements are alloyed together in specific combinations and amounts in order to achieve an alloy having desired properties and characteristics. In certain embodiments, strontium or cerium may be included as an additive. The resulting alloys are particularly suitable for forming various medical devices for implantation into the body of a patient.

Abstract: Provided herein are methods of treating a coronavirus infection in a patient, comprising administering an agent to the patient in an amount effective to increase cellular lysosomal pH in cells of the patient. As provided herein, the agent is one or more of an agent for reducing expression or activity of nuclear receptor coactivator 7 (NCOA7) in the patient, an RNAi agent or antisense reagent for knocking down expression of a v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA/p65) transcript, or a janus kinase (JAK) inhibitor, thereby increasing cellular lysosomal pH in cells of the patient.

Abstract: The invention relates generally to optically high transparency and high haze structures and, more particularly, to plastic, e.g., polymer, and glass structures having a sub-wavelength texture formed on a surface thereof, which is effective to impart the optical properties of high transparency and high haze to the structures. The texture is in a grass-like or needle-like form. Additionally, the optically high transparency and high haze structures may include a transparent conductor. Furthermore, the glass structures may exhibit a self-cleaning function.

Abstract: A system for determining snowpack characteristics includes a weight plate, at least one pressure sensor, and an inert plate surrounding the weight plate. The weight plate and the inert plate can be spaced apart from one another, and, in some cases, the weight plate has a perimeter and the inert plate surrounds the entirety of the perimeter of the weight plate with a gap formed therebetween.

Abstract: The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.

Abstract: An atrioventricular prosthesis device is provided. The device includes a frame at least partially defining and enclosing a central cavity, the frame having a distal portion, a proximal portion, and a middle portion connected therebetween. The device further includes a valve construct formed, at least in part, from a cell growth scaffold, at least partially disposed within the central cavity defined by the frame. The valve construct includes: an annular portion defining an aperture and being connected to the frame for positioning the valve construct within the central cavity of the frame, and a plurality of leaflets extending longitudinally and radially inward from the annular portion. The frame and valve construct are transitionable to a deployed state, in which a diameter of at least a portion of the frame and the valve construct substantially conform to a diameter of a tricuspid and/or mitral valve opening.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20—(Z)b—(Y)c—(R21)a—(X)d—R22—R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(?O), —S(?O)(?O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, cycloalkenediyl, substituted cycloalkenediyl, alkatrienyl, substituted alkatrienyl; X is —C(?O)—, —S(?O)(?O)—, or —N(H)C(?O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-

Abstract: Disclosed are anti-angiogenic agents that target Pfn1:actin interaction. Also disclosed are compounds for treating ocular diseases or conditions. Further disclosed are compounds for treating cancer.

Abstract: Compositions of matter and methods of identifying and making compositions of matter are disclosed. Some embodiments disclose making and chemically and/or compositionally tuning superconducting hydride materials. Some embodiments disclose an apparatus for making and compositionally tuning superconducting materials. Some embodiments disclose a composition of matter including a solid hydride exhibiting superconductivity at a temperature of at least 150 kelvin at an ambient pressure below 180 gigapascals, or at a temperature of at least 261 kelvin. In one or more embodiments, the superconductor includes a covalent metal hydride having at least three different chemical elements wherein an inter-atomic distance between the hydrogen in the covalent metal hydride is in a range of 1.1-2 angstroms. In yet further examples, the superconductor is formed using molecular exchange and compression of a Van der Waals solid.

Abstract: Described are methods for the recovery of uranium from uranium hexafluoride dissolved directly into ionic liquids.

Abstract: A mitochondrial-targeted PARP inhibitor is provided herein, as well as methods of making and using the mitochondrial-targeted PARP inhibitor.

Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.

Abstract: Various perovskite solar cell embodiments include a flexible metal substrate (e.g., including a metal doped TiO2 layer), a perovskite layer, and a transparent electrode layer (e.g., including a dielectric/metal/dielectric structure), wherein the perovskite layer is provided between the flexible metal substrate and the transparent electrode layer. Also, various tandem solar cell embodiments including a perovskite solar cell and either a quantum dot solar cell, and organic solar cell or a thin film solar cell.

Abstract: A method of forming a microneedle array can include forming a microneedle array that has one or more bioactive component. The microneedle array can include a base portion and plurality of microneedles extending from the base portion, and the one or more bioactive components can be combined with other components to exhibit specific release kinetics when the microneedle array is inserted into the skin of a patient.